The mechanistic model for potentiation of DSB-inducing agents by M3814 in solid tumors cells (16) predicted enhancement of p53-dependent response in p53 wild-type AML cells, but also suggested potentiation of DSB-inducing therapies in p53 dysfunctional cells. This evidence concerns the gene TP53 and acute myeloid leukemia.